| Budget Amount *help |
¥15,340,000 (Direct Cost: ¥11,800,000、Indirect Cost: ¥3,540,000)
Fiscal Year 2011: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2010: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2009: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2008: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
|
|---|
| Research Abstract |
Fully understanding of immune surveillance and regulation against cancers is needed to develop early-diagnosis and made-to-order immunotherapy for cancers by using cancer-specific peptides. In this study, SART-1 was identified to have strongest antigenicity among various cancer-specific peptides expressed on oral cancersand to play a central part in immune surveillance against oral cancers, indicating that SART-1 is most promisingly applicable to the treatment and diagnosis of oral cancers.In contrast, it was revealed that a tumor-associated antigen, RCAS1, was expressed on and secreted from oral cancers, induced apoptosis of activated T cells, and thussuppressed immune surveillance against oral cancers. To augment immune surveillance against oral cancers, it was strongly suggested that functional regulation of RCAS1, as well as inoculation of SART-1, should be achieved.
|
